Decheng Capital LLC Acquires 5,000 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Decheng Capital LLC grew its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 7.0% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,772 shares of the company's stock after acquiring an additional 5,000 shares during the period. Krystal Biotech accounts for 2.6% of Decheng Capital LLC's investment portfolio, making the stock its 7th biggest holding. Decheng Capital LLC owned 0.27% of Krystal Biotech worth $12,027,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of KRYS. US Bancorp DE grew its holdings in shares of Krystal Biotech by 8.7% during the 4th quarter. US Bancorp DE now owns 1,027 shares of the company's stock worth $161,000 after purchasing an additional 82 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Krystal Biotech by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 2,595 shares of the company's stock valued at $407,000 after buying an additional 82 shares in the last quarter. Crossmark Global Holdings Inc. boosted its stake in Krystal Biotech by 5.5% in the 4th quarter. Crossmark Global Holdings Inc. now owns 2,307 shares of the company's stock valued at $362,000 after buying an additional 121 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Krystal Biotech by 1.1% in the 4th quarter. Envestnet Asset Management Inc. now owns 11,630 shares of the company's stock valued at $1,822,000 after buying an additional 121 shares in the last quarter. Finally, Perigon Wealth Management LLC boosted its stake in Krystal Biotech by 1.5% in the 4th quarter. Perigon Wealth Management LLC now owns 8,289 shares of the company's stock valued at $1,200,000 after buying an additional 123 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

KRYS has been the topic of several recent analyst reports. Citigroup boosted their price target on Krystal Biotech from $206.00 to $215.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. HC Wainwright boosted their price target on Krystal Biotech from $221.00 to $240.00 and gave the company a "buy" rating in a research note on Monday. Chardan Capital lifted their price objective on Krystal Biotech from $212.00 to $218.00 and gave the company a "buy" rating in a research report on Thursday, February 20th. Jefferies Financial Group assumed coverage on Krystal Biotech in a research report on Wednesday, March 5th. They issued a "buy" rating and a $245.00 price objective for the company. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $222.71.

Krystal Biotech Price Performance

Shares of KRYS stock traded up $1.67 on Monday, reaching $169.73. 167,657 shares of the stock were exchanged, compared to its average volume of 295,598. The stock has a market cap of $4.90 billion, a PE ratio of 56.77 and a beta of 0.75. Krystal Biotech, Inc. has a one year low of $141.72 and a one year high of $219.34. The stock has a 50 day moving average price of $176.24 and a 200 day moving average price of $171.50.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, topping analysts' consensus estimates of $1.29 by $0.23. The company had revenue of $91.10 million during the quarter, compared to the consensus estimate of $91.35 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The firm's quarterly revenue was up 116.4% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.30 earnings per share. On average, research analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, CAO Kathryn Romano sold 750 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares in the company, valued at approximately $2,208,472.88. This represents a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Suma Krishnan sold 25,000 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares of the company's stock, valued at $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).